Our website use cookies to improve and personalize your experience and to display advertisements (if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies.

Vaccine trials for SA children

Vaccine trials for SA children

CHINA’S Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, according to Sinovac and its local partner Numolux Group. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement. The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya, including 2,000 in South Africa, they said. The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated…
Read More
COVID-19 vaccine trials in Africa: what’s promising, and what’s problematic

COVID-19 vaccine trials in Africa: what’s promising, and what’s problematic

SCIENTISTS are working around the clock to develop and test vaccines against SARS-CoV-2, the causative agent of COVID-19. Experts agree that widespread use of safe and effective vaccines will rapidly contain the COVID-19 pandemic, preventing transmission and disease. BENJAMIN KAGINA, Senior Research Officer, Vaccines For Africa Initiative, Faculty of Health Sciences, University of Cape Town A key step in the process of any vaccine development is clinical testing, which involves assigning a vaccine or a placebo to human subjects, then evaluating the health effects over a period of time. This testing helps to demonstrate safety in diverse human populations living…
Read More
Oxford COVID-19 trial will look at interim Phase III data after 53 infections – investigator

Oxford COVID-19 trial will look at interim Phase III data after 53 infections – investigator

ALISTAIR SMOUT and KATE KELLAND OXFORD University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.…
Read More